skip to content

Sarepta Therapeutics Announces Positive Safety and Efficacy Data from the SRP-9001 Micro-Dystrophin Gene Therapy Trial Published in JAMA Neurology

Investors

Investor updates
view all

stay updated

get the latest news and updates to your inbox.